Skip to main content

Power3 Hires Middle East Distributor for Proteomic-Based Breast Cancer Dx

NEW YORK (GenomeWeb News) — Power3 Medical Products said yesterday it has hired Bahrain-based Financial Advisory House to market and distribute a proteomics-based breast cancer test in 12 countries in the Middle East.
 
Under the agreement, FAH’s Medical Equipment Suppliers division will market and distribute Power3’s BC-SeraPro breast cancer diagnostic in Bahrain; Egypt; Iraq; Jordan; Kuwait; Lebanon; Saudi Arabia; Oman; Qatar; Syria; the United Arab Emirates; and Yemen.
 
BC-SeraPro is a proteomics-based blood serum diagnostic used for the early screening and diagnosis of breast cancer. FAH will market and distribute it to clinics and physicians in these countries, while the tests will be analyzed in Power3's Houston-based CLIA lab.
 
Financial terms of the agreement were not released.
 
“We selected the Middle East as our initial market because the healthcare systems in these particular countries are open to providing a test that offers new and innovative technologies for earlier detection of breast cancer,”Power3 CEO Steven Rash said in a statement.
 
The company also is seeking other distributors for the blood serum-based breast cancer test and is involved in discussions with international and domestic partners, it said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.